A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY,SAFETY AND TOLERABILITY OF PSILOCYBIN ORAL SOLUTION IN TREATING DEPRESSION AMONG ADULTS WITH (PTSD)

Sponsor name: APEX LABS INC.
Date of no objection letter: 2023–01–04
Trial status: PENDING

~

A 2-PART, PHASE 2A, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF PSILOCYBIN ORAL SOLUTION IN ADULTS WITH GENERALIZED ANXIETY DISORDER

Sponsor name: DIAMOND THERAPEUTICS
Date of no objection letter: 2023–01–12
Trial status: PENDING

~

DOES PSILOCYBIN CHANGE SYNAPTIC VESICULAR DENSITY IN THE BRAINS OF PATIENTS WITH MILD COGNITIVE IMPAIRMENT

Sponsor name:
CENTRE FOR ADDICTION AND MENTAL HEALTH (Toronto, Canada)
Date of no objection letter: 2023–01–05
Trial status: PENDING

~

PSILOCYBIN-ASSISTED EXISTENTIAL, ATTACHMENT AND RELATIONAL (PEARL) THERAPY FOR PATIENTS WITH ADVANCED CANCER: A PHASE II OPEN-LABEL TRIAL

Sponsor name: UNIVERSITY HEALTH NETWORK (Toronto, Canada)
Date of no objection letter: 2023–02–13
Trial status: PENDING

~

(Conference Presentation) 5-HT2A receptor agonism modifies neurovascular coupling and neuronal network activity in mice (Padawer-Curry et al.)

Published: Mar 17, 2023
Proc. SPIE PC12365, Neural Imaging and Sensing 2023

~

The Future for Psychedelic Agents in the Treatment of Posttraumatic Stress Disorder (Haycraft)

Published: Mar 24, 2023
The Journal for Nurse Practitioners

~

Cleansing Frames: How Digital ‘Consumer Reports’ of Cannabis and Psychedelics Normalise Drug-Taking and Neutralise its Counter-Cultural Potential (Ladegaard)

Published: Mar 24, 2023
Sociology